US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
SHANGHAI, April 2 (Bernama-AsiaNet) — On March 31, 2021, Jemincare Group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States. Preclinical data showed that JMB2002 can precisely occupy the key epitope of the receptor binding…

